Neuland Laboratories Overview
- Year Founded
-
1984
- Status
-
Public
- Employees
-
3,881
- Stock Symbol
-
524558
- Investments
-
3
- Share Price
-
$224.19
- (As of Friday Closing)
Neuland Laboratories General Information
Description
Neuland Laboratories Ltd is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The group has only one reportable segment manufacture of active pharmaceutical ingredients and allied services. It has presence in India, Europe, USA and North America, and Rest of the world.
Contact Information
Website
www.neulandlabs.comCorporate Office
- 11th Floor (5th Level), Phoenix IVY Building
- Plot Number. 573A-III, Road Number 82, Jubilee Hills
- Hyderabad, Telangana 500033
- India
Corporate Office
- 11th Floor (5th Level), Phoenix IVY Building
- Plot Number. 573A-III, Road Number 82, Jubilee Hills
- Hyderabad, Telangana 500033
- India
Neuland Laboratories Stock Performance
As of 13-Nov-2026, Neuland Laboratories’s stock price is $224.19. Its current market cap is $2.88B with 12.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $224.19 | $223.23 | $122.73 - $255.58 | $2.88B | 12.8M | 3.23K | $3.80 |
Neuland Laboratories Financials Summary
As of 30-Sep-2026, Neuland Laboratories has a trailing 12-month revenue of $249M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 2,854,846 | 1,635,006 | 1,797,830 | 961,797 |
| Revenue | 248,837 | 218,655 | 169,634 | 183,082 |
| EBITDA | 79,963 | 66,697 | 48,143 | 56,046 |
| Net Income | 48,808 | 41,193 | 30,761 | 36,248 |
| Total Assets | 315,411 | 310,552 | 254,840 | 219,749 |
| Total Debt | 35,639 | 31,930 | 18,370 | 11,438 |
Neuland Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neuland Laboratories Comparisons
Industry
Financing
Details
Neuland Laboratories Competitors (13)
One of Neuland Laboratories’s 13 competitors is Granules India, a Corporation company based in Hyderabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Granules India | Corporation | Hyderabad, India | ||||
| Emcure Pharmaceuticals | Formerly PE-Backed | Pune, India | ||||
| Aurobindo Pharma | Corporation | Hyderabad, India | ||||
| Laborate Pharmaceuticals India | Corporation | Panipat, India | ||||
| Hoechst Pakistan | Corporate Backed or Acquired | Karachi, Pakistan |
Neuland Laboratories Patents
Neuland Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026234714-A1 | A process for the preparation of sterile ensifentrine | Pending | 09-May-2025 | ||
| WO-2026220416-A1 | An improved process for the preparation of obicetrapib and its pharmaceutically acceptable salts thereof | Pending | 14-Apr-2025 | ||
| WO-2026009243-A1 | An improved process for the preparation of tirzepatide by using hybrid approach | Pending | 04-Jul-2024 | ||
| WO-2026003867-A1 | An improved process for the preparation of ensifentrine and its purification thereof | Pending | 24-Jun-2024 | ||
| WO-2025052429-A1 | An improved process for the preparation of tirzepatide | Inactive | 04-Sep-2023 | A61P3/10 |
Neuland Laboratories Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neuland Laboratories Investments & Acquisitions (3)
Neuland Laboratories’s most recent deal was a Corporate Asset Purchase with Neuland Laboratories (6 Acres Land Parcel in Domadugu, India) for . The deal was made on 03-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neuland Laboratories (6 Acres Land Parcel in Domadugu, India) | 03-Nov-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Arch Pharmalabs (Hyderabad Facility) | 13-Dec-2017 | Corporate Asset Purchase | Buildings and Property | ||
| Neuland Health Sciences | 08-Nov-2016 | Merger/Acquisition | Holding Companies |
Neuland Laboratories ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
28.73 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Neuland Laboratories Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Neuland Health Sciences | Hyderabad, India | 1993 |
Neuland Laboratories FAQs
-
When was Neuland Laboratories founded?
Neuland Laboratories was founded in 1984.
-
Where is Neuland Laboratories headquartered?
Neuland Laboratories is headquartered in Hyderabad, India.
-
What is the size of Neuland Laboratories?
Neuland Laboratories has 3,881 total employees.
-
What industry is Neuland Laboratories in?
Neuland Laboratories’s primary industry is Pharmaceuticals.
-
Is Neuland Laboratories a private or public company?
Neuland Laboratories is a Public company.
-
What is Neuland Laboratories’s stock symbol?
The ticker symbol for Neuland Laboratories is 524558.
-
What is the current stock price of Neuland Laboratories?
As of 13-Nov-2026 the stock price of Neuland Laboratories is $224.19.
-
What is the current market cap of Neuland Laboratories?
The current market capitalization of Neuland Laboratories is $2.88B.
-
What is Neuland Laboratories’s current revenue?
The trailing twelve month revenue for Neuland Laboratories is $249M.
-
Who are Neuland Laboratories’s competitors?
Granules India, Emcure Pharmaceuticals, Aurobindo Pharma, Laborate Pharmaceuticals India, and Hoechst Pakistan are some of the 13 competitors of Neuland Laboratories.
-
What is Neuland Laboratories’s annual earnings per share (EPS)?
Neuland Laboratories’s EPS for 12 months was $3.80.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
